多替阿巴拉米片效果如何

(Suimeikai) is a new fixed-dose compound preparation against human immunodeficiency virus (HIV) infection containing three ingredients: dolutegravir, abacavir and lamivudine. Dolutegravir (Suimeike) is suitable for the treatment of HIV infection in adults and adolescents aged 12 years and above. Current drugs for the treatment of AIDS have shortcomings such as high incidence of adverse reactions, poor tolerance, and many drug interactions, and there is the possibility of drug resistance after long-term medication. Doptabalamid Tablets (Suimeike) has certain clinical advantages over existing treatment options, adding new treatment options to the clinic.

How effective is Dolutegra Abalami Tablets?

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%. From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in dolutea (Simeike) is significantly less than that of the other two drugs, making it less likely to develop drug resistance.

  Each tablet of Dolutegravir (Simeike) contains 50 mg of dolutegravir (DTG), 600 mg of abacavir (ABC) and 300 mg of lamivudine (3TC). Dolutegra Abalamid Tablets (Suimeike) should be taken orally under the guidance of a physician with experience in treating HIV infection. Docetabalamid (Simeika) is not affected by food. Dosage: One tablet, once daily. It is not recommended for those whose creatinine clearance is less than 50ml/min. 

The above is the introduction about (Sui Mei Kai), I hope it can help everyone. If patients have other questions about the drug (such as drug price, purchasing channels, etc.), they can consult the medical companion travel service. 

Recommended hot articles: /newsDetail/85352.html